QNCX — Quince Therapeutics Balance Sheet
0.000.00%
- $234.98m
- $226.21m
Annual balance sheet for Quince Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 134 | 107 | 90.2 | 75.1 | 40.8 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 138 | 112 | 93.7 | 77.4 | 44 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.1 | 1.43 | 0.684 | 0.619 | 0.813 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 189 | 133 | 104 | 168 | 114 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 17 | 14.2 | 3.07 | 9.57 | 7.28 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 17.2 | 14.6 | 3.32 | 82.8 | 84.3 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 172 | 119 | 101 | 85.1 | 30.1 |
| Total Liabilities & Shareholders' Equity | 189 | 133 | 104 | 168 | 114 |
| Total Common Shares Outstanding |